Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) and Entera Bio (NASDAQ:ENTX – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends.
Institutional & Insider Ownership
91.0% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 14.1% of Entera Bio shares are held by institutional investors. 0.2% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 10.6% of Entera Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Vertex Pharmaceuticals and Entera Bio”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vertex Pharmaceuticals | $12.00 billion | 10.19 | $3.95 billion | $16.86 | 28.57 |
| Entera Bio | $40,000.00 | 3,635.14 | -$11.44 million | ($0.27) | -10.93 |
Vertex Pharmaceuticals has higher revenue and earnings than Entera Bio. Entera Bio is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current recommendations and price targets for Vertex Pharmaceuticals and Entera Bio, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vertex Pharmaceuticals | 0 | 3 | 22 | 0 | 2.88 |
| Entera Bio | 1 | 0 | 1 | 0 | 2.00 |
Vertex Pharmaceuticals presently has a consensus target price of $559.61, suggesting a potential upside of 16.17%. Entera Bio has a consensus target price of $9.00, suggesting a potential upside of 205.08%. Given Entera Bio’s higher probable upside, analysts clearly believe Entera Bio is more favorable than Vertex Pharmaceuticals.
Volatility and Risk
Vertex Pharmaceuticals has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500. Comparatively, Entera Bio has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500.
Profitability
This table compares Vertex Pharmaceuticals and Entera Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vertex Pharmaceuticals | 35.51% | 23.86% | 17.13% |
| Entera Bio | N/A | -83.31% | -70.83% |
Summary
Vertex Pharmaceuticals beats Entera Bio on 10 of the 14 factors compared between the two stocks.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
About Entera Bio
Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
